The AVMAPKI FAKZYNJA CO-PACK generated $30.9 million net product revenue from its May–Dec 2025 launch, including $17.5 million in Q4, supported by nearly 300 prescribers. Around 75% of top target institutions have adopted the therapy, with group purchasing organizations integrating it into EMR pathways for second-line use. More than half of prescriptions have come from academic centers, and time-to-fill averages 12–14 days.

Verastem ended 2025 with $205 million in cash and a pro forma balance of $234.4 million, providing runway into the first half of 2027. Management targets the LGSOC franchise to become self-sustaining by the second half of 2027, backed by ongoing reimbursement and a planned digital promotional campaign.

Enrollment is complete in the RAMP 301 phase III trial, with top-line analysis expected in mid-2027 to potentially expand approval regardless of KRAS status. The Japan RAMP 201J study showed 57% response in KRAS-mutant and 22% in wild-type patients, and the company plans to engage PMDA for conditional approval. For metastatic pancreatic cancer, RAMP 205 enrollment is finished with a Q2 update expected, and the VS-7375 oral KRAS program is advancing early safety evaluations.